Sanofi is battle-ready: "We welcome competition, not least from our great colleagues at Leo Pharma" French pharmaceutical firm Sanofi has already spun gold within an area that Leo Pharma enters with major drug candidate. Photo: Benoit Tessier/Reuters/Ritzau Scanpix BY BENJAMIN WERNER CHRISTENSEN & SIGNE FERSLEV PEDERSEN, FINANS, TRANSLATED BY NIELSINE NIELSEN Published: 04.01.21 at 23:02 French pharmaceutical firm Sanofi has shown the way for the Danish pharmaceutical company Leo Pharma in terms of conquering the market for a new type of treatment for eczema and asthma. Already a subscriber? Log in. Read the whole article Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial. Access all locked articles Receive our daily newsletters Access our app First name: Last name: E-mail address: Password: I accept the terms and conditions An error has occured. Please try again later. Create trial Get full access for you and your coworkers. Start a free company trial today More from MedWatch Board chair at Coloplast and Lundbeck warns against large pay rises Companies have a responsibility to help combat inflation by keeping pay rises in check during contract negotiations, says Lars Rasmussen. Ellab slapped with customs fine over US imports Danish medtech producer Ellab broke US customs rules and is now paying the price. China approves Y-mabs drug Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties. CEO gets "taste of own medicine" by participating in vaccine trial Expres2ion CEO Bent U. Frandsen is one of 3,000 volunteers participating in a phase III trial of Bavarian Nordic’s Covid-19 booster candidate. If the vaccine reaches the market, Expres2ion will be entitled to royalties. FDA approves Covid-19 jabs as boosters for infants The US Food and Drug Administration has approved the use of Moderna and Pfizer/Biontech’s coronavirus vaccines as boosters for children as young as six months old. Print Print Increase text size Increase text size Decrease text size Decrease text size Further reading EU Commission proposes staggered transition to new medtech requirements after industry warnings FDA ruling to trigger royalty payments for Novo Nordisk FDA approves new sensor for insulin pens Eli Lilly and Boehringer Ingelheim drug proves effective in children with type 2 diabetes Danish agency joins competition authority chorus in criticizing Oticon Medical sale Related articles Media: Europe aims for vaccine approval on Dec. 23 Former Novo Nordisk employee plans to revolutionize market for insulin pens Novo Nordisk withdraws press statement – had misleading marketing Novo Nordisk completes acquisition of Emisphere Technologies Novo Nordisk submits obesity drug for FDA approval Departing Leo Pharma executive plans to follow Genmab's example for new biotech: "It's a major aspiration, but it's can be done"